|Home | About | Journals | Submit | Contact Us | Français|
Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.
Patients had ECOG performance status 0–2 and normal organ function. Dacarbazine was administered on day 1 and dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50mg b.i.d. of dasatinib and 800mgm−2 of dacarbazine. Available pre-treatment biopsies were sequenced for BRAF, NRAS, and C-Kit mutations.
Dose-limiting toxicity was reached at dasatinib 70mg b.i.d./dacarbazine 1000mgm−2, and was predominantly haematological. In 29 patients receiving dasatinib 70mg b.i.d., the objective response rate (ORR) was 13.8%, the clinical benefit rate (ORR+SD) was 72.4%, the 6-month progression-free survival (PFS) was 20.7%, and the 12-month overall survival (OS) was 34.5%. Two out of three patients who were wild type for BRAF, NRAS, and c-KIT mutations had confirmed partial responses, and one had a minor response.
The recommended phase II dose is dasatinib70mg b.i.d with dacarbazine 800mgm−2. PFS and OS data for dasatinib at 70mg b.i.d. with dacarbazine compared favourably with historical controls. Preliminary data support evaluating tumour mutation status further as a biomarker of response.
The incidence of melanoma is increasing rapidly worldwide. In the United States, an estimated 8700 deaths (Jemal et al, 2010) result annually from this disease. The development of metastatic disease is associated with a dismal prognosis (Barth et al, 1995) and, until recently, the FDA-approved therapeutic options were not associated with a survival benefit (Atkins et al, 1999, 2000; Chapman et al, 2011). Ipilimumab, an anti-CTLA-4 antibody, does confer a modest survival benefit in this population, but survival is still limited (median overall survival (OS)=10–11.2 months; Hodi et al, 2010; Robert et al, 2011). Therapeutic strategies targeting tumour-driving oncogenes now promise to revolutionise the treatment of melanoma. In particular, the BRAF inhibitors vemurafenib and GSK2118643 show evidence of clinical activity in a large proportion of patients whose tumours harbour BRAFV600E/K mutations (Flaherty et al, 2010; Kefford et al, 2010; Chapman et al, 2011). However, about half of the cutaneous melanoma tumours do not harbour BRAF mutations, and even in patients with these mutations, responses to vemurafenib are transient, lasting a median of 6.7 months (Chapman et al, 2011). Therefore, the identification of additional therapeutic targets in melanoma is urgently needed.
Given the role of invasion and metastasis in the clinical progression of melanoma, strategies inhibiting these processes could substantially impact the clinical course of the disease. Src and the related Src family kinases signal through multiple downstream intermediaries including STAT3 (Yu et al, 1995), FAK, and β-catenin (Irby et al, 2005), and Src activation has been implicated in decreased tumour cell adhesion, increased invasiveness, and increased motility (Buettner et al, 2008). Src activation has been implicated in the pathogenesis of colon (Irby et al, 1999; Kline et al, 2008), lung (Song et al, 2006), pancreas (Trevino et al, 2006), breast (Hiscox et al, 2006; Jallal et al, 2007; Morgan et al, 2009), and prostate cancer (Nam et al, 2005; Kotha et al, 2006). In uveal melanoma, Src activation has been associated with the MAP kinase pathway activation (Maat et al, 2009). Src is also frequently activated in cutaneous melanoma (Niu et al, 2002; Homsi et al, 2009; Eustace et al, 2010), and Src overexpression increases cutaneous melanoma cell proliferation and decreases adhesion (Boukerche et al, 2010). Conversely, Src inhibition leads to decreased proliferation and migration in melanoma cell lines (Eustace et al, 2008, 2010).
Dasatinib is a multi-targeted small-molecule kinase inhibitor that inhibits Src and c-Kit in low nanomolar range. C-Kit is mutated in approximately 15–20% of acral and mucosal melanomas (Beadling et al, 2008; Satzger et al, 2008; Torres-Cabala et al, 2009), and marked objective tumour responses have been observed in patients with exon 11 and exon 13 c-Kit mutant melanoma treated with dasatinib. In one case, this occurred even after disease progression on imatinib (Woodman et al, 2009). In melanoma cell lines that have not been selected for c-Kit mutations, dasatinib decreases cellular proliferation (Eustace et al, 2010) and enhances apoptosis (Niu et al, 2002), and dasatinib decreases cell migration even in cells in which it has no antiproliferative effect (Eustace et al, 2008, 2010). Dasatinib may also inhibit the formation of new melanoma lung metastases in vivo (Fraser et al, 2010). Dasatinib monotherapy is only modestly active in melanoma patients unselected for c-Kit mutations. In a phase II clinical trial, 36 metastatic melanoma patients were treated with dasatinib dosed at 70–100mg PO b.i.d. Two partial responses were reported and the 6-month progression-free survival (PFS) rate was 13% (Kluger et al, 2011). One responding patient had a confirmed c-Kit mutation in exon 13; the other was a c-KIT wild type. Four c-KIT wild-type patients were described with prolonged stabilisation of disease lasting up to 136 weeks. Common dose-limiting toxicities associated with dasatinib in this trial included pleural effusions, dyspnoea, fatigue, and diarrhoea.
In addition to its single agent activity, cell-culture experiments have demonstrated an antiproliferative synergy between dasatinib and chemotherapeutic agents including cisplatin (Homsi et al, 2009) and temozolomide (Eustace et al, 2008) in c-Kit wild-type melanoma. Dacarbazine is a commonly employed alkylating agent with single-agent activity in advanced melanoma (Luikart et al, 1984; Chapman et al, 1999; Middleton et al, 2000; Schadendorf et al, 2006). We conducted a phase I clinical trial of dasatinib in combination with dacarbazine, to determine the safety and tolerability of this regimen in patients with advanced melanoma and to identify a recommended phase II dose. Selective dose expansion cohorts were evaluated for preliminary evidence of efficacy. Tumours from a subset of patients were also evaluated for BRAF, NRAS, and c-Kit mutations as a potential biomarker of response.
This study was initially designed as a two-part study, with dose-escalation and dose-expansion cohorts. The first three of these cohorts included twice-daily dosing of dasatinib, and the remaining two cohorts included once-daily dosing. The dose escalation for the twice-daily dasatinib dosing schedule was based on a standard phase I dose escalation (3+3) scheme (Ratain et al, 1993). Dose expansion was eventually carried out in multiple cohorts for evaluation of dose-limiting toxicity (DLT) events and for better estimation of efficacy and toxicity. A total of five cohorts were evaluated to identify the maximum tolerated dose (MTD) of dacarbazine in combination with dasatinib (Bristol-Myers Squibb, New York, NY, USA). Dosing was as follows: cohort 1, dasatinib 50mg PO b.i.d, dacarbazine 800mgm−2; cohort 2, dasatinib 70mg PO b.i.d, dacarbazine 800mgm−2; cohort 3, dasatinib 70mg PO b.i.d, dacarbazine 1000mgm−2; cohort 4, dasatinib 140mg PO daily, dacarbazine 1000mgm−2; and cohort 5, dasatinib 100mg PO daily, dacarbazine 1000mgm−2. Written informed consent was obtained from all patients before the initiation of pre-treatment screening procedures. The Scientific Review Committees and the Institutional Review Boards at the Moffitt Cancer Center in Tampa, FL, USA, and at the University of California, San Francisco, CA, USA, approved the trial. Accrual began in January 2008 and was completed in August 2009.
Eligible patients had unresectable stage III or stage IV melanoma. Patients were required to have measurable or evaluable disease, and prior treatment with dacarbazine or temozolomide was not allowed. All patients were required to have an ECOG performance status of 0–2, adequate bone marrow function (absolute neutrophil count >1.5 × 109l−1, haemoglobin >9gdl−1, platelets >100 × 109l−1), renalfunction (creatinine <1.5 times the upper limit of normal), and hepatic function (total bilirubin <1.5 times the upper limit of normal, AST and ALT <2.5 times the upper limit of normal). Patients with vascular events within 6 months were excluded, as were patients with QTc prolongation (>470ms) and ongoing cardiac dysrhythmias. Patients with leptomeningeal disease were excluded, but neurologically intact patients with treated brain metastasis that had no evidence of recurrence for at least 12 weeks were eligible.
All patients were treated with dacarbazine on day 1 of each 21-day cycle, and dasatinib was taken orally on treatment days 2 through 19. Dasatinib was not given on treatment days 20, 21, and 1, due to concern that it could decrease cellular proliferation and diminish the efficacy of cytotoxic chemotherapy. Concurrent use of potent CYP3A4 inhibitors or of medications known to prolong the QT interval was prohibited. Before each dacarbazine infusion, patients were pre-medicated with dexamethasone, ondansetron, and lorazepam. Treatment was continued until disease progression, withdrawal of consent, or the development of unacceptable treatment-related toxicity.
Pre-treatment assessments included a complete history and physical examination, laboratories including a complete blood count, a comprehensive metabolic panel, and a 12-lead electrocardiogram. Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 at weekly follow-up visits during the first 21-day treatment cycle, and every three weeks thereafter. Dose-limiting toxicities were defined as any grade 4 haematological toxicity (except asymptomatic grade 4 neutropenia lasting 7 days or less); prolonged grade 3 or 4 thrombocytopenia (>7 days) or thrombocytopenia associated with bleeding, requiring platelet transfusion; any grade 3 or 4 non-haematological toxicity, despite optimal supportive care; and any toxicity considered unacceptable by the study principal investigator. The MTD was initially defined as the highest dose level at which fewer than two out of six patients (<33%) experienced a DLT in cycle 1, but post-DLT period events were ultimately taken into consideration for defining the MTD. After the 21-day DLT period, dose modifications were made for febrile neutropenia (T>38.5°, ANC <1000mm−3); grade 3 or 4 thrombocytopenia, persistent neutropenia (ANC <1000mm−3) or thrombocytopenia (platelet count <100000μl−1) on day 1 of any treatment cycle; grade 2 or higher liver function abnormalities; diarrhoea; and any other grade 3 or higher non-haematological toxicity other than fever, chills, and flu-like symptoms.
Planned secondary endpoints included overall response rate (ORR) by the Response Evaluation Criteria in Solid Tumours (RECIST v1.0), OS and PFS. Patients receiving at least two cycles of treatment and those taken off study, early for clinical disease progression were considered evaluable for response. Tumour assessments were made at baseline and at the end of every second cycle (i.e. every 6 weeks). Partial and complete responses were defined by the best treatment response achieved. Stable disease was defined as maintenance of the sum of lesions diameters between a 30% reduction and a 20% increase of overall tumour size over 12 weeks or longer. Patients were assessed for adverse events on the basis of the clinical and laboratory data on treatment days 1, 8, and 15 of the first 21-day cycle, then every 3 weeks on day 1 of each subsequent cycle.
Descriptive Kaplan–Meier survival analysis was performed and subgroup survival comparisons using log-rank were performed using SPSS version 17 (Chicago, IL, USA).
A post-hoc analysis of tumour mutation status as a predictor of response was performed on the 12 of 46 evaluable patients who had tissue available for analysis. Available pre-treatment, formalin-fixed, paraffin-embedded specimens were used to prepare 5-μm sections. Sections were microdissected to minimise stromal contamination and were genotyped using the PCR for known oncogenic mutations in BRAF exon 15, NRAS exons 1 and 2, c-Kit exons 9, 11, 13, 17, and 18, GNAQ exon 5, and GNA11 exon 5. The two patients with tumours positive for BRAF mutations were identified through screening for a subsequent clinical trial of the BRAF inhibitor PLX-4032 (NCT00949702).
A total of 51 patients were consented and screened for this study. One patient was found to be ineligible. Another patient entered the study with a diagnosis of melanoma of the soft parts, a disease that is now considered a sarcoma subtype. The patient was included in toxicity, but not response assessments. A total of 49 patients with melanoma, who received any treatment on study, were also considered evaluable for toxicity. Another 46 patients were considered to be evaluable for response. Two inevaluable melanoma patients did not complete two cycles of therapy due to toxicity (N=2), and one withdrew consent (N=1) and did not have restaging scans. Complete patient demographics are listed in Table 1.
The most common grade 3 and 4 adverse events were haematological (50% of patients overall), including neutropenia, anaemia, and thrombocytopenia (Tables 2 and and3).3). No DLTs were observed in cohorts 1 and 2. One of the first three patients in cohort 3 (dacarbazine 1000mgm−2, dasatinib 70mg PO b.i.d) developed dose-limiting thrombocytopenia, and the cohort was expanded to 6 and then to 14 patients to gain additional information regarding treatment-associated toxicity. The sample sizes for cohort expansions were based on the observation of latent (post-DLT period) toxicities rather than pre-planned statistical considerations. Two additional patients in the expansion of cohort 3 developed dose-limiting febrile neutropenia. After the DLT period, one patient developed refractory grade 3 diarrhoea, and another patient had a myocardial infarction that was considered possibly related to treatment. The latent toxicities observed in expansion cohort 3 precluded further clinical development at these dose levels, and dacarbazine 800mgm−2 with dasatinib 70mg PO b.i.d was designated as the MTD for twice-daily dosing of dasatinib. Cohort 2 was subsequently expanded to a total of 19 patients. This regimen was generally well tolerated, with 9 of 19 patients (47%) experiencing non-dose-limiting (generally transient) grade 3 and 4 haematological adverse events. Grade 3 and 4 non-hematologic adverse events were limited to one patient with grade 3 dyspnoea, two patients with grade 3 hyponatraemia, and one patient with grade 3 hyperglycaemia.
Two regimens with once-daily dasatinib dosing were also evaluated. One out of three patients in cohort 4 (dacarbazine 1000mgm−2 with dasatinib 140mg PO daily) developed dose-limiting grade 3 thrombocytopenia and grade 3 dyspnoea during the DLT period, and a second patient developed grade 3 dyspnoea on cycle 2 day 15. On the basis of these events, dacarbazine 1000mgm−2 with dasatinib 140mg PO daily was thought to be too toxic for further development. There were no DLTs in a total of 11 patients treated in cohort 5 (dacarbazine 1000mgm−2 with dasatinib 100mg PO daily). Five patients in this cohort had non-dose-limiting grade 3 and 4 haematological toxicities, one patient developed grade 3 fatigue, and one patient had an episode of grade 3 gastrointestinal bleeding that was probably treatment related. Further expansion of cohort 5 was not pursued due to the failure of once-daily dasatinib dosing to induce objective tumour responses in these 11 patients.
A total of 4 out of 29 evaluable patients (13.8%) receiving dasatinib 70mg PO b.i.d. had partial responses by RECIST (Table 4), and 17 patients had stabilisation of disease for a clinical benefit rate (ORR+SD) of 72.4%. There were no objective responses in the other three cohorts. Prolonged stabilisation of disease was observed in all cohorts and in 26 out of 46 patients (56.5%) overall. Clinical benefit (PR+SD) was observed in 30 of 46 patients (65.2%). The median PFS in all patients was 13.4 weeks and the median OS was 40.6 weeks. The median PFS in cohorts 1–5 was 5.1, 14.0, 13.4, 12.0, and 11.6 weeks, respectively. The median OS in cohorts 1–5 was 63.9, 40.6, 40.9, 28.6, and 40.9 weeks, respectively. In all, 3 out of 12 patients genotyped were wild type for BRAF, NRAS, c-KIT, GNAQ, and GNA11 mutations. Two of these patients had objective tumour responses and one had a minor response (Figure 1). In patients receiving dasatinib 70mg PO b.i.d., the 6-month PFS rate was 20.7% and the 12-month OS rate was 34.5%.
There were no differences in PFS on the basis of gender, normal vs elevated LDH, age, metastatic stage, or ocular vs non-ocular primary. Median PFS by genotype was 5.7, 6, 17.3, and 34 weeks for patients with BRAF (N=2), NRAS (N=4), GNAQ/GNA11 (N=3), and wild-type (N=3) mutation status, respectively. Patients with clinical benefit from dacarbazine and dasatinib had significantly longer OS than those without (51.6 vs 22.3 weeks, P<0.01), and there was a trend towards worse OS in patient with ocular vs non-ocular primaries (22.9 vs 40.9 weeks, n.s.). There were no differences in OS on the basis of gender, age, or metastatic stage, and there were not enough events in the genotyped patients to allow calculation of the median OS in all groups.
The Src family kinases has critical roles in the process of cancer invasion (Kim et al, 2009), and preclinical data indicates that Src inhibition may add to tumour control in advanced malignancies including melanoma (Eustace et al, 2008; Homsi et al, 2009; Fraser et al, 2010). In the current study, we show that dasatinib, a Src/abl kinase inhibitor, can be safely combined with dacarbazine at an adequate dose intensity. Dose expansion cohorts at three levels were accrued to profile-delayed toxicities and to get a better estimate of efficacy. Toxicities were primarily haematological, and treatment discontinuations were required with post-cycle 1 therapy in patients receiving dasatinib 70mg PO b.i.d with dacarbazine 1000mgm−2 IV every 3 weeks. At this dose level, objective responses were noted in 2 out of 11 (18.2%) patients and clinical benefit in 7 out of 11 (54.5%) patients. Treatment was better tolerated in patients receiving 70mg PO b.i.d with dacarbazine 800mgm−2. Objective tumour responses were observed in 2 patients (11%), and clinical benefit was observed in 11 out of 18 patients (61.1%) in this cohort. On the basis of these findings, the latter dose level would be appropriate for further clinical trials. In contrast to a recent phase II study of dasatinib monotherapy (Kluger et al, 2011), grade 3 and 4 pulmonary and gastrointestinal toxicities were infrequent, occurring in only 2 of 33 patients (6.1%) receiving dasatinib 70mg PO b.i.d. Grade 3 and 4 pleural effusions were not observed. The lower incidence of these side effects in the present study may be due to the steroid premedication used with dacarbazine, dacarbazine itself, or the dasatinib dosing schedule that included a three-day pause in dasatinib dosing on treatment days 20, 21, and 1. Of note, the first 17 patients treated in the prior study started with dasatinib dosed at 100mg PO b.i.d, and the majority of these patients required early treatment interruptions due to treatment-associated toxicity. The incidence of pulmonary and gastrointestinal toxicity was markedly lower in patients enrolled subsequently at a dose of 70mg PO b.i.d.
Dasatinib combined with dacarbazine appears to be more active than either agent alone, with the caveat that cross-trial comparisons must be interpreted with extreme caution. In a phase II trial, dasatinib monotherapy yielded a median PFS of 8 weeks and a 6 month PFS rate of 13% (Kluger et al, 2011). Similarly, patients treated with dacarbazine alone typically demonstrate objective disease progression on the first restaging scan (e.g. Chapman et al, 2011). In contrast, the median PFS for patients treated with dacarbazine+dasatinib was 13.4 weeks and the 6-month PFS rate was 20.7%. Furthermore, both the 6-month PFS and 12-month OS rates for dacarbazine and dasatinib compare favourably with benchmarks established in the Korn et al (2008) meta-analysis based on 42 trials, which completed accrual between 1975 and 2005 (6-month PFS=20.7% vs 14.5%, 95% CI 12.9–16.1% 12-month OS=34.5% vs 25.5%, 95% CI 23.6–27.4%). These findings suggest that the addition of dasatinib to dacarbazine may decrease the dissemination of advanced melanoma lesions, consistent with reductions in tumour cell invasion and migration induced by dasatinib in pre-clinical studies (Eustace et al, 2008, 2010).
The current study supports further exploration of BRAF/NRAS/KIT wild-type status as one of several candidate biomarkers that could help to identify patients who are most likely to benefit from dacarbazine with dasatinib. The absence of BRAF and NRAS mutations in melanoma cell lines is associated with a greater sensitivity to dasatinib in vitro (Journe et al, 2010). Genotyping data from the current study were limited by tissue availability and subject to non-random selection. However, the finding that two of four clinical responders to dasatinib with dacarbazine did not have the BRAF/NRAS/c-Kit mutations is intriguing and bears further evaluation in the context of a phase II clinical trial. Additional candidate biomarkers could also be explored in such a trial including caveolin-1, an Src substrate that influences c-Src kinase activity. Caveolin-1 expression in melanoma is associated with increased cellular proliferation (Felicetti et al, 2009; Trimmer et al, 2010), and in some studies, enhanced tumour cell invasion and migration (Felicetti et al, 2009). Several studies have identified elevated caveolin-1 expression as a biomarker of response to dasatinib in breast, lung, and prostate cancer cells (Finn et al, 2007; Huang et al, 2007; Wang et al, 2007). Furthermore, in a phase II trial of single-agent dasatinib, five out of six metastatic melanoma patients with objective tumour-size reductions had elevated caveolin-1 expression levels before treatment (Jilaveanu et al, 2011).
Preliminary data suggest that c-Kit inhibitors, including dasatinib, are highly active in c-Kit mutant melanoma (Lutzky et al, 2008; Carvajal et al, 2009, 2011; Woodman et al, 2009; Handolias et al, 2010; Guo et al, 2011), and dasatinib is currently in phase II testing in patients with solar, mucosal, and acral melanoma (‘Dasatinib in Advanced Mucosal, Acral, or Solar Melanoma,' ClinicalTrials.gov, no date). However, in the current study, none of the genotyped patients who benefitted clinically harboured c-Kit mutations.
In summary, the combination of dacarbazine and dasatinib is well tolerated at clinically relevant dose levels. Dacarbazine dose at 800mgm−2 combined with 70-mg dasatinib twice daily warrants further evaluation in the context of a phase II clinical trial in advanced melanoma, and this trial could further evaluate candidate biomarkers for response. These biomarkers, if validated, may help to identify the optimal target population for treatment with dacarbazine and dasatinib in combination.
Research support for this trial was provided by Bristol-Myers-Squibb.
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
Presented in part at the Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2010.